Aclaris Therapeutics
ACRS
100 hedge funds and large institutions have $579M invested in Aclaris Therapeutics in 2016 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 40 increasing their positions, 7 reducing their positions, and 6 closing their positions.
717% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 6
471% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 7
300% more funds holding in top 10
Funds holding in top 10: 2 → 8 (+6)
84% more ownership
Funds ownership: 0% → 84% (+84%)
72% more funds holding
Funds holding: 58 → 100 (+42)
46% more capital invested
Capital invested by funds: $396M → $579M (+$183M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$21.2M |
| 2 |
PC
PointState Capital
New York
|
+$18.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$15.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11.5M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$55.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$39.6M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$23.1M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$4.85M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RCM
101
RA Capital Management
Boston,
Massachusetts
| – | -$39.6M | -1,547,152 | Closed |
|
|
TAM
102
Tocqueville Asset Management
New York
| – | -$845K | -33,000 | Closed |
|
103
Citadel Advisors
Miami,
Florida
| – | -$238K | -9,303 | Closed |
|
|
EMG
104
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$233K | -9,117 | Closed |
|
|
SO
105
STRS Ohio
Columbus,
Ohio
| – | -$207K | -8,100 | Closed |
|
|
LTFS
106
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$82K | -3,200 | Closed |
|
ACRS Hedge Fund Activity: Q4 2016 in Review
100 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2016, worth a combined $579M — up 46% from $396M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ACRS positions and 6 closed out — a net gain of 43 holders — while 40 added to existing stakes and 7 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $21.2M. The largest seller was Fidelity Investments, cutting an estimated $55.9M.
- 100 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2016, up from 58 in Q3 2016.
- Funds reported $579M of Aclaris Therapeutics stock for Q4 2016, up 46% quarter-over-quarter.
- 49 funds opened new Aclaris Therapeutics positions in Q4 2016 and 6 closed out, a net change of +43 holders.
- The largest Aclaris Therapeutics buyer in Q4 2016 was Perceptive Advisors, an estimated $21.2M added.
- The largest Aclaris Therapeutics seller in Q4 2016 was Fidelity Investments, an estimated $55.9M sold.
Based on aggregated 13F filings for Q4 2016.